Nitrofurantoin Oral Suspension, USP 25mg/ 5 mL was launched in the US markets.
Carnegie Pharmaceuticals has acquired six (6) products.
Erythromycin Ethylsuccinate for oral Suspension USP, 200 mg/5 mL and 400 mg/5 mL (NDA Product; Eryped® 200 and Eryped® 400)
Erythromycin Ethylsuccinate Film-Coated Tablets USP, 400 mg (E.E.S. 400®)
Erythromycin Delayed Release Tablets USP, 250 mg, 333 mg and 500 mg (ERY-TAB®)
Erythromycin Delayed Release Pellets USP, 250 mg
Erythromycin Film-Coated Tablets USP, 250 mg & 500 mg
Erythromycin Stearate Tablets USP, 250 mg
Our commercial plan is to launch Eryped Oral Suspension and E.E.S 400 Tablets in December 2024, and the remaining products in 2025. For more information about these products, please call our sales team member, Paul Krauthauser at 267-772-0879 or Micthell Goldberg at 267-679-3008.
Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.
Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.
Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.
Carnegie Pharmaceuticals LLC received approval for Oxcarbazepine Oral Suspension USP, 300 mg/5 mL from USA FDA.
Carnegie Pharmaceuticals LLC received approval for Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg & 50 mcg from US FDA.
Carnegie Pharmaceuticals LLC acquired three approved products given below. The plan is to launch these products by the end of 2024.
Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to US FDA.
Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to US FDA.
Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to US FDA.
Carnegie Pharmaceuticals, LLC signed a contract to supply its products in Chile.
Carnegie Pharmaceuticals is pleased to announce the approval of Etravirine Tablets, 100mg and 200mg.
FDA approved Oseltamivir Phosphate for Oral Suspension, 6 mg/mL that was developed and commercially manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to the US FDA.
Carnegie Pharmaceuticals, LLC successfully completed FDA inspection (GMP and PAI) without any observations.
Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.
Leading Pharma commercially launches Aminocaproic Acid Tablets USP, 500mg and 1000mg that is manufactured at Carnegie Pharma facilities.
Carnegie Pharmaceuticals, LLC succesfully completed the pre-approval inspection by the FDA.
FDA approved Doxepin Hydrochloride Capsules USP, 10 mg , 25 mg , 50 mg , 75 mg , 100 mg , that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
FDA approved Doxepin Hydrochloride Capsules USP, 150 mg, that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
FDA approved Aminocaproic Acid Tablets USP, 500mg and 1000mg that was developed and manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
FDA approved Aminocaproic Acid Oral Solution, 1.25g/5mL that was developed and manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
Carnegie Pharmaceuticals, LLC received DEA Manufacturing License (Schedule 2-5).
Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.
Carnegie Pharmaceuticals successfully completed its first FDA inspection.
Carnegie Pharmaceuticals LLC signed an agreement with Alter Pharma, Belgium to develop and commercially manufacture a NDA product for the US market.
FDA approved Clomipramine Hydrochloride Capsules, 25 mg, 50 mg and 75 mg, that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.
Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.
Carnegie Pharmaceuticals, LLC announces the completion of the manufacturing plant located at its Delran Facilities.
Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.
Carnegie Pharmaceuticals has moved to a 50,000 square feet facility in Delran, NJ. The new facility has state of the art laboratories and manufacturing capabilities in the solid and liquid dosage forms.
Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.
Carnegie Pharmaceuticals, LLC announces the submission of the first ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.
Carnegie Pharmaceuticals acquired its future manufacturing facility. The facility is approximately 50,000 square feet located in Southern New Jersey. This facility will enable Carnegie to file and commercially supply products to the market from its own site.
Carnegie Pharmaceuticals appoints Dr. Venkat Dandu as the Asst. Manager of Analytical Research & Development. Dr. Dandu previously worked in the Analytical R&D department for more than 10 years at Lupin Pharma and Oncova Therapeutics.
Carnegie Pharmaceuticals appoints Sumreen Naqvi as the Manager of Analytical Research & Development. Ms. Naqvi previously worked in the analytical research and development department of Johnson and Johnson, Sun Pharma (formerly URL Mutual) and Teva Pharmaceuticals (formerly Barr Labs).
Carnegie Pharmaceuticals appoints Sunil Shah as the Director of Operations. Mr. Shah previously worked in the operations department for twenty eight years at various capacities and most recently as the Manager of Operations in Sun Pharma (formerly URL Mutual Pharma).
Carnegie Pharmaceuticals appoints Ajay Raju, Esq. as Company's Legal Advisor.
Carnegie Pharmaceuticals appoints Indigo Global Corp. as Company's Executive-in-Residence Consultancy partner.
Carnegie Pharmaceuticals and Leading Pharma extend their development agreement by one more year.
Carnegie Pharmaceuticals initiated the development of following products:
Need a Solution?